Table 1 Baseline Characteristics of Study Participants with and without Prevalent Diabetes at Baseline examination.

From: Using a Targeted Proteomics Chip to Explore Pathophysiological Pathways for Incident Diabetes– The Malmö Preventive Project

 

All subjects (n = 1707)

Subjects without prevalent diabetes (n = 1026)

Subjects with prevalent diabetes (n = 681)

p-value

Age (years)

67.4 (±6.0)

66.9 (±6.1)

68.1 (±5.9)

<0.001

Sex (% female)

498 (29.1)

331 (32.2)

167 (24.4)

0.001

BMI

28.3 (±4.3)

27.4 (±3.9)

29.8 (±4.6)

<0.001

SBP (mmHg)

146.9 (±19.8)

145.3 (±19.2)

149.1 (±20.6)

<0.001

HT (%)

1069 (62.6)

570 (55.6)

499 (73.3)

<0.001

FPG (mmol/l)

6.2 (5.6–7.4)

5.8 (5.3–6.2)

7.8 (7.1–9.2)

<0.001

TG (mmol/l)

1.3 (0.9–1.8)

1.1 (0.8–1.6)

1.5 (1.0–2.0)

<0.001

HDL (mmol/l)

1.3 (1.0–1.5)

1.3 (1.1–1.6)

1.2 (1.0–1.4)

<0.001

Cystatin C (mg/l)

1.06 (0.95–1.20)

1.05 (0.95–1.19)

1.08 (0.95–1.24)

0.002

  1. BMI; body mass index, SBP; systolic blood pressure; DBP; diastolic blood pressure, HT; hypertension, FPG; fasting plasma glucose, TG; triglycerides, HDL; high-density lipoprotein cholesterol. Values are displayed as means (±standard deviation) or, for skewed variables, medians and interquartile (25–75) range.
Back to article page